Denali Therapeutics (DNLI)
NASDAQ:DNLI
Want to see DNLI full AI Analyst Report?
Total Valuation
Denali Therapeutics has a market cap or net worth of $2.96B. The enterprise value is $2.61B.
Market Cap$2.96B
Enterprise Value$2.61B
Share Statistics
Denali Therapeutics has 158,709,730 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding158,709,730
Owned by Insiders6.65%
Owned by Institutions39.34%
Financial Efficiency
Denali Therapeutics’s return on equity (ROE) is -0.51 and return on invested capital (ROIC) is -52.59%.
Return on Equity (ROE)-0.51
Return on Assets (ROA)-0.45
Return on Invested Capital (ROIC)-52.59%
Return on Capital Employed (ROCE)-0.53
Revenue Per Employee0.00
Profits Per Employee-1.16M
Employee Count443
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Denali Therapeutics is ―. Denali Therapeutics’s PEG ratio is -0.36.
PE Ratio―
PS Ratio0.00
PB Ratio2.86
Price to Fair Value2.86
Price to FCF-6.86
Price to Operating Cash Flow-8.43
PEG Ratio-0.36
Income Statement
In the last 12 months, Denali Therapeutics had revenue of 0.00 and earned -512.54M in profits. Earnings per share was -2.97.
Revenue0.00
Gross Profit-11.18M
Operating Income-555.34M
Pretax Income-512.44M
Net Income-512.54M
EBITDA-497.63M
Earnings Per Share (EPS)-2.97
Cash Flow
In the last 12 months, operating cash flow was -412.34M and capital expenditures -6.89M, giving a free cash flow of -419.23M billion.
Operating Cash Flow-412.34M
Free Cash Flow-419.23M
Free Cash Flow per Share-2.64
Dividends & Yields
Denali Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.88
52-Week Price Change35.12%
50-Day Moving Average20.25
200-Day Moving Average17.20
Relative Strength Index (RSI)52.71
Average Volume (3m)1.77M
Important Dates
Denali Therapeutics upcoming earnings date is Jul 30, 2026, TBA (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateJul 30, 2026
Ex-Dividend Date―
Financial Position
Denali Therapeutics as a current ratio of 9.16, with Debt / Equity ratio of 4.32%
Current Ratio9.16
Quick Ratio9.16
Debt to Market Cap<0.01
Net Debt to EBITDA0.33
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Denali Therapeutics has paid 102.00K in taxes.
Income Tax102.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Denali Therapeutics EV to EBITDA ratio is -5.49, with an EV/FCF ratio of -6.48.
EV to Sales0.00
EV to EBITDA-5.49
EV to Free Cash Flow-6.48
EV to Operating Cash Flow-6.63
Balance Sheet
Denali Therapeutics has $987.68M in cash and marketable securities with $40.05M in debt, giving a net cash position of $947.64M billion.
Cash & Marketable Securities$987.68M
Total Debt$40.05M
Net Cash$947.64M
Net Cash Per Share$5.97
Tangible Book Value Per Share$5.78
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Denali Therapeutics is $35.91, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$35.91
Price Target Upside74.57% Upside
Analyst ConsensusStrong Buy
Analyst Count14
Revenue Growth Forecast―
EPS Growth Forecast-7.88%